Vicore is an innovative clinical-stage pharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential. The company is establishing a portfolio in respiratory diseases, including idiopathic pulmonary fibrosis (IPF). Buloxibutid (C21) is a first-in-class orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) currently in phase 2a development for IPF. Almee™ (an investigational medical device in clinical development) is a digital therapeutic based on cognitive behavioral therapy created to address the psychological impact of living with pulmonary fibrosis. Almee has received Breakthrough Device Designation from the FDA, reflecting its potential to have transformative impact. Using its unique expertise in ATRAG chemistry and biology, Vicore is further fueling its pipeline with several new therapies across additional potential indications. The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see www.vicorepharma.com.


Clinical Trials

Medical Devices

Pharmaceutical

Vicore Pharma AB

Vicore Pharma AB's headquarters in Stockholm, Sweden

Ahmed Mousa

Camilla Nygren

Professor Bertil E. Lindmark M.D.

Jimmie Hofman

Mikael Nygård

Nina Carlén

Johan Raud

Hans Jeppsson

Bertil Lindmark

Description

People (5)

Jimmie Hofman

Hans Jeppsson

Johan Raud

Jacob Gunterberg

Karin Eklund Vanderpol

Jobs